JP7289420B6 - 肺癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物 - Google Patents

肺癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物 Download PDF

Info

Publication number
JP7289420B6
JP7289420B6 JP2019555941A JP2019555941A JP7289420B6 JP 7289420 B6 JP7289420 B6 JP 7289420B6 JP 2019555941 A JP2019555941 A JP 2019555941A JP 2019555941 A JP2019555941 A JP 2019555941A JP 7289420 B6 JP7289420 B6 JP 7289420B6
Authority
JP
Japan
Prior art keywords
amhrii
antibody
tumor
nsclc
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019555941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516655A (ja
JP7289420B2 (ja
JP2020516655A5 (https=
Inventor
バレット，ジャン－マルク
プロスト，ジャン－フランソワ
ラマー，メディ
デゴヴェ，ステファン
デュブレイユ，オリヴィエ
ニコラ，アンドレ
ムジュール，ディディエ
Original Assignee
エクセリクシス， インク．
アンスティテュート キュリー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクセリクシス， インク．, アンスティテュート キュリー filed Critical エクセリクシス， インク．
Publication of JP2020516655A publication Critical patent/JP2020516655A/ja
Publication of JP2020516655A5 publication Critical patent/JP2020516655A5/ja
Application granted granted Critical
Publication of JP7289420B2 publication Critical patent/JP7289420B2/ja
Publication of JP7289420B6 publication Critical patent/JP7289420B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
JP2019555941A 2017-04-14 2018-04-13 肺癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物 Active JP7289420B6 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305446.1 2017-04-14
EP17305446 2017-04-14
PCT/EP2018/059553 WO2018189381A1 (en) 2017-04-14 2018-04-13 Amhrii-binding compounds for preventing or treating lung cancers

Publications (4)

Publication Number Publication Date
JP2020516655A JP2020516655A (ja) 2020-06-11
JP2020516655A5 JP2020516655A5 (https=) 2021-05-20
JP7289420B2 JP7289420B2 (ja) 2023-06-12
JP7289420B6 true JP7289420B6 (ja) 2023-06-30

Family

ID=58672546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019555941A Active JP7289420B6 (ja) 2017-04-14 2018-04-13 肺癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物

Country Status (9)

Country Link
US (1) US20230227566A1 (https=)
EP (1) EP3609919A1 (https=)
JP (1) JP7289420B6 (https=)
KR (2) KR102759138B1 (https=)
CN (1) CN110944665B (https=)
BR (1) BR112019021495A8 (https=)
CA (1) CA3058541A1 (https=)
MX (2) MX2019012136A (https=)
WO (1) WO2018189381A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020516668A (ja) * 2017-04-14 2020-06-11 ガママブス ファルマ 癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物
EP3917967A4 (en) * 2019-02-01 2023-02-08 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Microenvironment sensors to regulate engineered gene expression
WO2020243679A1 (en) * 2019-05-31 2020-12-03 Detti Laura Anti-mullerian hormone receptor binding peptides
EP4034151A1 (en) * 2019-09-27 2022-08-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of müllerian inhibiting substance inhibitors for treating cancer
US20230078601A1 (en) * 2020-01-31 2023-03-16 The Cleveland Clinic Foundation Anti-mullerian hormone receptor 2 antibodies and methods of use
KR20240149925A (ko) * 2022-02-16 2024-10-15 더 클리브랜드 클리닉 파운데이션 Amhr2-ed 암 백신 제제
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013534408A (ja) 2010-05-12 2013-09-05 エルエフビー・バイオテクノロジーズ ヒト抗−ミューラー管ホルモンｉｉ型レセプターを指向する新規な変異ヒト化１２ｇ４抗体及びそのフラグメント
JP2020516668A (ja) 2017-04-14 2020-06-11 ガママブス ファルマ 癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
WO2005005615A2 (en) * 2003-07-08 2005-01-20 Fox Chase Cancer Center Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer
EP1918304A1 (en) 2006-11-02 2008-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)
US20100233689A1 (en) * 2007-03-22 2010-09-16 The General Hospital Corporation Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
CA2837472A1 (en) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
FR2984750B1 (fr) * 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
EP3331569A1 (en) 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
US11261225B2 (en) * 2017-02-10 2022-03-01 Institute For Cancer Research Chimera of bone morphogenic protein 2 and the Müllerian-inhibiting substance type II receptor binding region of Müllerian-inhibiting substance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013534408A (ja) 2010-05-12 2013-09-05 エルエフビー・バイオテクノロジーズ ヒト抗−ミューラー管ホルモンｉｉ型レセプターを指向する新規な変異ヒト化１２ｇ４抗体及びそのフラグメント
JP2020516668A (ja) 2017-04-14 2020-06-11 ガママブス ファルマ 癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cell Reports, 2016, Vol. 16, pp. 657-671

Also Published As

Publication number Publication date
US20230227566A1 (en) 2023-07-20
RU2019131542A3 (https=) 2021-08-18
JP2020516655A (ja) 2020-06-11
WO2018189381A1 (en) 2018-10-18
RU2019131542A (ru) 2021-05-14
KR102759138B1 (ko) 2025-01-23
BR112019021495A2 (pt) 2020-05-12
CN110944665A (zh) 2020-03-31
JP7289420B2 (ja) 2023-06-12
KR20250017758A (ko) 2025-02-04
KR20200014277A (ko) 2020-02-10
MX2019012136A (es) 2020-07-20
CN110944665B (zh) 2024-04-19
EP3609919A1 (en) 2020-02-19
CA3058541A1 (en) 2018-10-18
BR112019021495A8 (pt) 2023-05-02
MX2024003228A (es) 2024-07-10

Similar Documents

Publication Publication Date Title
JP7289420B6 (ja) 肺癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物
CN111363041B (zh) 新型抗-pd-l1抗体
TWI755791B (zh) 用於治療癌症之pd-1 / pd-l1抑制劑
CN106103486B (zh) 抗ox40抗体和使用方法
JP6840127B2 (ja) がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
KR102644408B1 (ko) 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
US20220144959A1 (en) Amhrii-binding compounds for preventing or treating cancers
AU2018243020A1 (en) Medicinal composition for treating cancer
KR20150003169A (ko) Ｄｌｌ3 조절물질들 및 사용 방법
EP3344658A1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
RU2797506C2 (ru) Соединения, связывающие AMHRII, для профилактики или лечения раковых заболеваний легкого
RU2816523C2 (ru) Соединения, связывающие AMHRII, для профилактики или лечения раковых заболеваний
WO2021009761A1 (en) Combination therapy for the treatment of cancer
BR122024021123A2 (pt) Uso de um agente de ligação ao amhrii humano para a prevenção ou tratamento de cânceres de pulmão e método para determinar se um indivíduo que sofre de um câncer de pulmão é responsivo a um tratamento de câncer
JP2026514105A (ja) 癌の治療のためのｇｒｅｍ１拮抗薬が関与する併用療法
BR122024021115A2 (pt) Uso de um agente de ligação ao amhrii humano e método para determinar se um indivíduo é responsivo a um tratamento de câncer com um agente de ligação ao amhrii
CN120957750A (zh) 用于治疗癌症的涉及grem1拮抗剂的组合疗法
HK40032298B (en) Novel anti-pd-l1 antibodies
HK40032298A (en) Novel anti-pd-l1 antibodies
HK1260737B (en) Novel anti-pd-l1 antibodies
HK1260737A1 (en) Novel anti-pd-l1 antibodies
NZ616809A (en) Anti-b7-h3 antibody
HK1230525A1 (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230120

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230216

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20230216

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230322

R150 Certificate of patent or registration of utility model

Ref document number: 7289420

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150